BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAFV600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC) Meeting Abstract
| Authors: | Kopetz, S.; Grothey, A.; Yaeger, R.; Ciardiello, F.; Desai, J.; Kim, T. W.; Maughan, T.; Van Cutsem, E.; Wasan, H. S.; Yoshino, T.; Edwards, M. L.; Golden, A.; Gollerkeri, A.; Tabernero, J. |
| Abstract Title: | BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cet) ± chemotherapy for first-line treatment (tx) of BRAFV600E-mutant (BRAFV600) metastatic colorectal cancer (mCRC) |
| Meeting Title: | 2022 ASCO Gastrointestinal Cancers Symposium |
| Journal Title: | Journal of Clinical Oncology |
| Volume: | 40 |
| Issue: | 4 Suppl. |
| Meeting Dates: | 2022 Jan 20-22 |
| Meeting Location: | San Francisco, CA |
| ISSN: | 0732-183X |
| Publisher: | American Society of Clinical Oncology |
| Date Published: | 2022-02-01 |
| Language: | English |
| ACCESSION: | WOS:000770995900207 |
| DOI: | 10.1200/JCO.2022.40.4_suppl.TPS211 |
| PROVIDER: | wos |
| Notes: | Meeting Abstract: TPS211 -- Meeting was conducted online as well as in person -- Source: Wos |
